All stage 1, stage 2, and stage 3 tumor samples tested had down-regulation of SLC6A15. Later-stage tumors (stage 3 and stage 4) showed down-regulated REN levels compared to normal thyroid tissue. This evidence concerns the gene SLC6A15 and neoplasm.